Literature DB >> 33720992

Epstein-Barr virus nuclear antigen 3C (EBNA3C) interacts with the metabolism sensing C-terminal binding protein (CtBP) repressor to upregulate host genes.

Makoto Ohashi1,2, Mitchell Hayes2, Kyle McChesney1,2, Eric Johannsen1,2.   

Abstract

Epstein-Barr virus (EBV) infection is associated with the development of specific types of lymphoma and some epithelial cancers. EBV infection of resting B-lymphocytes in vitro drives them to proliferate as lymphoblastoid cell lines (LCLs) and serves as a model for studying EBV lymphomagenesis. EBV nuclear antigen 3C (EBNA3C) is one of the genes required for LCL growth and previous work has suggested that suppression of the CDKN2A encoded tumor suppressor p16INK4A and possibly p14ARF is central to EBNA3C's role in this growth transformation. To directly assess whether loss of p16 and/or p14 was sufficient to explain EBNA3C growth effects, we used CRISPR/Cas9 to disrupt specific CDKN2A exons in EBV transformed LCLs. Disruption of p16 specific exon 1α and the p16/p14 shared exon 2 were each sufficient to restore growth in the absence of EBNA3C. Using EBNA3C conditional LCLs knocked out for either exon 1α or 2, we identified EBNA3C induced and repressed genes. By trans-complementing with EBNA3C mutants, we determined specific genes that require EBNA3C interaction with RBPJ or CtBP for their regulation. Unexpectedly, interaction with the CtBP repressor was required not only for repression, but also for EBNA3C induction of many host genes. Contrary to previously proposed models, we found that EBNA3C does not recruit CtBP to the promoters of these genes. Instead, our results suggest that CtBP is bound to these promoters in the absence of EBNA3C and that EBNA3C interaction with CtBP interferes with the repressive function of CtBP, leading to EBNA3C mediated upregulation.

Entities:  

Year:  2021        PMID: 33720992      PMCID: PMC7993866          DOI: 10.1371/journal.ppat.1009419

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


  58 in total

1.  Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha.

Authors:  M A Cotter; E S Robertson
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

2.  Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype.

Authors:  Kris Covens; Bert Verbinnen; Nick Geukens; Isabelle Meyts; Frans Schuit; Leentje Van Lommel; Marc Jacquemin; Xavier Bossuyt
Journal:  Blood       Date:  2013-04-23       Impact factor: 22.113

3.  Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase.

Authors:  Jason S Knight; Nikhil Sharma; Erle S Robertson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

4.  Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells.

Authors:  Seiji Maruo; Yi Wu; Satoko Ishikawa; Teru Kanda; Dai Iwakiri; Kenzo Takada
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-11       Impact factor: 11.205

5.  Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP.

Authors:  Lenka Skalska; Robert E White; Melanie Franz; Michaela Ruhmann; Martin J Allday
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

Review 6.  The pathogenesis of Epstein-Barr virus persistent infection.

Authors:  David A Thorley-Lawson; Jared B Hawkins; Sean I Tracy; Michael Shapiro
Journal:  Curr Opin Virol       Date:  2013-05-15       Impact factor: 7.090

7.  EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth.

Authors:  Andrew Cooper; Eric Johannsen; Seiji Maruo; Ellen Cahir-McFarland; Diego Illanes; David Davidson; Elliott Kieff
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

8.  The coupling of synthesis and partitioning of EBV's plasmid replicon is revealed in live cells.

Authors:  Asuka Nanbo; Arthur Sugden; Bill Sugden
Journal:  EMBO J       Date:  2007-09-13       Impact factor: 11.598

9.  First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.

Authors:  Dagmar Pich; Paulina Mrozek-Gorska; Mickaël Bouvet; Atsuko Sugimoto; Ezgi Akidil; Adam Grundhoff; Stephan Hamperl; Paul D Ling; Wolfgang Hammerschmidt
Journal:  mBio       Date:  2019-09-17       Impact factor: 7.867

10.  EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency.

Authors:  Christine T Styles; Quentin Bazot; Gillian A Parker; Robert E White; Kostas Paschos; Martin J Allday
Journal:  PLoS Biol       Date:  2017-08-03       Impact factor: 8.029

View more
  3 in total

1.  The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines.

Authors:  Weiyue Ding; Chong Wang; Yohei Narita; Hongbo Wang; Merrin Man Long Leong; Alvin Huang; Yifei Liao; Xuefeng Liu; Yusuke Okuno; Hiroshi Kimura; Benjamin Gewurz; Mingxian Teng; Shuilin Jin; Yoshitaka Sato; Bo Zhao
Journal:  J Virol       Date:  2022-09-12       Impact factor: 6.549

Review 2.  Epigenetic control of the Epstein-Barr lifecycle.

Authors:  Rui Guo; Benjamin E Gewurz
Journal:  Curr Opin Virol       Date:  2021-12-08       Impact factor: 7.121

3.  ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cells.

Authors:  Nicholas Van Sciver; Makoto Ohashi; Dhananjay M Nawandar; Nicholas P Pauly; Denis Lee; Kathleen R Makielski; Jillian A Bristol; Sai Wah Tsao; Paul F Lambert; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2021-11-08       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.